Cargando…

Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas

The Mycobacterium tuberculosis-harboring granuloma with a necrotic center surrounded by a fibrous capsule is the hallmark of tuberculosis (TB). For a successful treatment, antibiotics need to penetrate these complex structures to reach their bacterial targets. Hence, animal models reflecting the pul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walter, Kerstin, Kokesch-Himmelreich, Julia, Treu, Axel, Waldow, Franziska, Hillemann, Doris, Jakobs, Nikolas, Lemm, Ann-Kathrin, Schwudke, Dominik, Römpp, Andreas, Hölscher, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211424/ https://www.ncbi.nlm.nih.gov/pubmed/34871095 http://dx.doi.org/10.1128/aac.01588-21

Ejemplares similares

A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Antimycobacterial Activity
por: Ganapathy, Uday S., et al.
Publicado: (2021)

Antimycobacterial Effects of Everolimus in a Human Granuloma Model
por: Ashley, David, et al.
Publicado: (2020)

Generalized Granuloma Annulare Treated with Monthly Rifampicin, Ofloxacin, and Minocycline Combination Therapy
por: Garg, Shilpa, et al.
Publicado: (2013)

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
por: Diaz Miqueli, A, et al.
Publicado: (2009)

ToF-SIMS analysis of osteoblast-like cells and their mineralized extracellular matrix on strontium enriched bone cements
por: Kokesch-Himmelreich, Julia, et al.
Publicado: (2013)

Discovery and Preclinical Development of Antigiardiasis Fumagillol Derivatives
por: Padia, Janak, et al.
Publicado: (2020)

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1
por: Park, A. Young J., et al.
Publicado: (2022)

Non-necrotizing colonic granuloma induced by schistosomiasis
por: Swe, Thein, et al.
Publicado: (2016)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013)

Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections
por: Plaunt, Adam J., et al.
Publicado: (2021)

Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
por: Re, D, et al.
Publicado: (2002)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Photodynamic diagnosis of ovarian cancer using hexaminolaevulinate: a preclinical study
por: Lüdicke, F, et al.
Publicado: (2003)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models
por: Martínez-Pérez, Carlos, et al.
Publicado: (2016)

Spontaneous necrotizing granuloma of the cerebellum: a case report
por: Godbe, Kerilyn N., et al.
Publicado: (2020)

Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology
por: Yin, Ting, et al.
Publicado: (2017)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
por: Ong, Voon, et al.
Publicado: (2016)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
por: Nutley, B P, et al.
Publicado: (2005)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland
por: Ruokoniemi, Päivi, et al.
Publicado: (2014)

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
por: Bozec, A, et al.
Publicado: (2008)

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin
por: Wu, X, et al.
Publicado: (2009)

Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models
por: Cao, S, et al.
Publicado: (2014)

Preclinical studies of targeted α therapy for breast cancer using (213)Bi-labelled-plasminogen activator inhibitor type 2
por: Allen, B J, et al.
Publicado: (2003)

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
por: Dredge, K, et al.
Publicado: (2011)

Antimycobacterial and cytotoxicity activity of microcystins
por: Ramos, Daniela Fernandes, et al.
Publicado: (2015)

N-Alkoxyphenylhydroxynaphthalenecarboxamides and Their Antimycobacterial Activity
por: Gonec, Tomas, et al.
Publicado: (2016)

Antimycobacterial Activity of Salicylanilide Benzenesulfonates
por: Krátký, Martin, et al.
Publicado: (2012)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

Sterile necrotizing and non-necrotizing granulomas in a heart transplant patient with history of PTLD: A unique finding
por: Piening, Nicholas, et al.
Publicado: (2019)

Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
por: Rottmann, Matthias, et al.
Publicado: (2020)

Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model
por: Arcaroli, J J, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g2hvdp4fkh900260evogftkeoj